GLP-1s, Specialty Drugs, and the New Pharmacy Cost Conversation

Not long ago, the pharmacy cost conversation for most employer health plans was relatively contained within generic substitution rates, formulary tier management, and PBM rebate performance—important issues, but manageable ones that employers and their advisors had frameworks for addressing.

Then pharmacy changed in ways that those frameworks weren't built to handle.

The rise of GLP-1 receptor agonists for weight management, the expanding pipeline of specialty biologics and gene therapies, and the acceleration of direct-to-consumer pharmaceutical marketing have collectively created a pharmacy cost environment unlike anything most employer plans have faced before. The old playbook is not equipped for it, and a lot of employers are feeling the consequences without understanding why.

The GLP-1 Moment

To understand what is happening in employer pharmacy right now, it helps to start with GLP-1s.

Drugs like semaglutide were first approved for type 2 diabetes management. The clinical evidence supporting that use is strong, and for members managing diabetes or obesity-related conditions like cardiovascular disease, sleep apnea, or osteoarthritis, the case for coverage is often medically compelling. That is an important starting point, because the instinct to simply exclude these drugs from coverage—which many employers have acted on—ignores the clinical reality for a meaningful segment of the covered population.

But the cost reality is equally impossible to ignore. List prices for GLP-1s prescribed for weight loss can exceed $10,000 per member per year. Utilization has expanded rapidly, driven by both genuine clinical need and aggressive direct-to-consumer advertising that has created demand far beyond the population for whom these drugs were originally designed. For a self-funded employer with a few hundred covered employees, even a handful of GLP-1 prescriptions can move the pharmacy trend line in a way that shows up at renewal.

The challenge is that there is no clean answer here. Covering GLP-1s broadly exposes the plan to significant cost growth. Excluding them entirely creates clinical gaps for members with legitimate medical need and creates workforce friction at a time when benefits are a meaningful part of the talent conversation. Neither extreme serves employers well, and neither is an adequate substitute for a thoughtful coverage strategy.

What employers actually need is a nuanced, data-informed approach that establishes clear clinical criteria, distinguishes between diabetes management and weight loss indications, includes step therapy protocols, and is monitored actively enough to catch utilization patterns before they become budget events. That is not a set-it-and-forget-it decision, but an ongoing clinical and financial management challenge.

The Broader Specialty Drug Picture

GLP-1s are the most visible chapter in a longer story. Specialty drugs now represent a disproportionate share of pharmacy spend for most employer plans, and the pipeline of high-cost treatments continues to expand in ways that are difficult to anticipate and even harder to budget for without the right analytical infrastructure.

Gene therapies with list prices in the millions of dollars are no longer theoretical. Biologics for autoimmune conditions, oncology treatments, and rare disease therapies each carry their own clinical complexity and cost profile. This is where the relationship between employer and pharmacy benefit manager deserves more scrutiny than it typically receives. PBMs operate with their own financial interests—in rebate arrangements, in specialty pharmacy channel management, and in formulary design— and those interests don't always align cleanly with the employer's goal of managing cost while supporting member health. 

Employers who delegate pharmacy management entirely to their PBM and assume it is being handled well are taking a risk that the current specialty drug environment has made considerably larger than it used to be.

What a Smarter Pharmacy Strategy Actually Requires

Managing pharmacy cost in this environment is not a matter of finding the right PBM and letting it run. It requires ongoing engagement, analytical capability, and a willingness to ask questions that most brokers are not equipped to ask.

Formulary design needs to keep pace with a rapidly evolving drug landscape. Coverage policies for GLP-1s should distinguish between clinical indications, establish evidence-based prior authorization criteria, and build in step therapy requirements that ensure members have accessed appropriate lower-cost alternatives before reaching the highest-cost treatments. Those policies also need to be revisited regularly, because the clinical evidence and the drug pipeline are both moving targets.

PBM contract performance requires active verification. Rebate guarantees, pricing commitments, and formulary compliance provisions are meaningful on paper, but are only as valuable as the employer's ability to confirm they are being honored. Regular contract audits and performance reviews with a partner who understands the clinical and financial profile of claims are a baseline requirement of responsible plan management.

The Conversation Has Changed

There was a time when pharmacy was a supporting character in the employer benefits cost story. That time is over. For many plans, pharmacy is now a primary driver of cost trend, and increasingly, the most complex and consequential area of benefits management that employers face. The advisors who are equipped for that reality bring clinical knowledge, contract expertise, and analytical capability together in a way that the traditional broker model was never designed to support. 

GLP-1s will not be the last high-cost drug category to reshape employer pharmacy economics. What comes next is already in the pipeline. The employers who build the right advisory relationships and oversight infrastructure now will be far better positioned to manage it, and far less likely to encounter the costs of that change as a surprise.